Related Experiment Video
Updated: Aug 15, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
New strategies for improving heart failure management: a primary care perspective
1Primary Care Division, Ralph H Johnson VA Medical Center, Charleston, SC 29403, USA.
Insights
Primary care practitioners manage most heart failure cases. Effective treatment involves targeting neurohormonal abnormalities with medications like ACE inhibitors and beta-blockers to reduce hospitalizations and mortality.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Heart failure is primarily managed by primary care practitioners.
- Disease progression is linked to neurohormonal activation, not just hemodynamic issues.
Purpose of the Study:
- To provide practice guidelines for heart failure management.
- To outline pharmacologic treatments targeting neurohormonal pathways.
Main Methods:
- Review of Consensus Recommendations for the Management of Chronic Heart Failure.
- Guideline-based pharmacologic therapy including diuretics, ACE inhibitors, and beta-blockers.
Main Results:
- Pharmacologic antagonism of neurohormonal abnormalities reduces heart failure morbidity and mortality.
- Combination therapy with diuretics, ACE inhibitors, and beta-blockers is recommended for systolic dysfunction and fluid retention.
Conclusions:
- Current guidelines recommend specific pharmacologic strategies for heart failure.
- Combination therapy significantly reduces hospitalization and death risk in heart failure patients.
Abstract:
Most patients with heart failure today are treated by primary care practitioners, not cardiologists. The Consensus Recommendations for the Management of Chronic Heart Failure, developed by the Advisory Council to Improve Outcomes Nationwide in Heart Failure, provide practice guidelines for the prevention, diagnosis, and treatment of heart failure. Although hemodynamic abnormalities contribute to the symptoms of heart failure, disease progression is attributable to neurohormonal abnormalities, primarily activation of the renin-angiotensin system and the sympathetic nervous system. Pharmacologic treatment that antagonizes these neurohormonal abnormalities reduces the morbidity and mortality associated with heart failure. Guidelines recommend that patients with systolic dysfunction and symptoms of fluid retention receive a diuretic followed by an angiotensin-converting enzyme inhibitor, and, once the patient is euvolemic, a beta-blocker. Digoxin may be added to therapy for patients with persistent symptoms or rapid atrial fibrillation. Clinical trials have shown that such combination regimens reduce the risk of hospitalization and death in patients with heart failure.
More Related Videos
Related Concept Videos
Rheumatic Heart Disease III: Medical Management
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies
Heart Failure VII: Nursing Interventions
Cardiomyopathy V: Interprofessional Care

